RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 3, 2013
Released January 2014

Featuring interviews with Drs David J Kerr, Matthew Kulke, Peter C Enzinger and Bert H O’Neil. (Text and Audio Content)

CE Disclosures and Faculty Information

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.


    • Counsel patients with Stage II colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options based on an evaluation of this information.
    • Effectively apply the results of practice-changing clinical research to the selection and sequencing of chemobiologic regimens for patients with metastatic CRC.
    • Summarize key findings from clinical studies of emerging and newly approved therapeutic regimens for patients with advanced pancreatic cancer, and use this information to guide treatment decision-making.
    • Use clinical and molecular biomarkers to optimize the selection of systemic therapy for patients with gastric or gastroesophageal cancer.
    • Educate patients with unresectable metastatic neuroendocrine tumors of the GI tract regarding approved and novel treatment approaches and their associated risks and benefits.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with advanced hepatocellular carcinoma.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr KerrAdvisory Committee: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline; Contracted Research: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: EMD Serono Inc, Genomic Health Inc. Dr KulkeConsulting Agreements: Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr EnzingerData and Safety Monitoring Board: Taiho Pharmaceutical Co Ltd. Dr O’NeilAdvisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, Onyx Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Genomic Health Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc, Lilly, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    January 2014
    Expiration date: January 2015

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 3, 2013
Released January 2014

Featuring interviews with Drs David J Kerr, Matthew Kulke, Peter C Enzinger and Bert H O’Neil. (Text and Audio Content)

Read print: